179 related articles for article (PubMed ID: 33844093)
1. The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythematosus with disease activity.
Zeng Y; Zhang Y; Lin Y; Wang X; Chen Q; Huang Q; Wang J; Jiang L; Xiao Y
Clin Exp Med; 2021 Nov; 21(4):611-619. PubMed ID: 33844093
[TBL] [Abstract][Full Text] [Related]
2. Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus.
Zeng Y; Lin Q; Yu L; Wang X; Lin Y; Zhang Y; Yan S; Lu X; Li Y; Li W; Xiao Y
BMC Immunol; 2021 Dec; 22(1):82. PubMed ID: 34961474
[TBL] [Abstract][Full Text] [Related]
3. Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus.
Zeng Y; Lin Y; Wang X; Zhang Y; Peng F; Wang J; Jiang L; Liang S; Xiao Y
Clin Rheumatol; 2020 Sep; 39(9):2619-2629. PubMed ID: 32189150
[TBL] [Abstract][Full Text] [Related]
4. Distribution of IgG subclass anti-nuclear antibodies (ANAs) in systemic lupus erythematosus.
Zeng Y; Zhang Y; Chen Q; Huang Q; Lin Y; Wang X; Wang JJ; Jiang L; Xiao Y
Lupus; 2021 May; 30(6):901-912. PubMed ID: 33622075
[TBL] [Abstract][Full Text] [Related]
5. CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?
Schiffer L; Worthmann K; Haller H; Schiffer M
Clin Exp Immunol; 2015 Jan; 179(1):85-9. PubMed ID: 25138065
[TBL] [Abstract][Full Text] [Related]
6. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
Ezzat M; El-Gammasy T; Shaheen K; Shokr E
Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
[TBL] [Abstract][Full Text] [Related]
7. Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis.
Bao YQ; Wang JP; Dai ZW; Mao YM; Wu J; Guo HS; Xia YR; Ye DQ
Clin Rheumatol; 2020 Jan; 39(1):281-290. PubMed ID: 31523787
[TBL] [Abstract][Full Text] [Related]
8. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
[TBL] [Abstract][Full Text] [Related]
9. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE).
Schiffer L; Kümpers P; Davalos-Misslitz AM; Haubitz M; Haller H; Anders HJ; Witte T; Schiffer M
Nephrol Dial Transplant; 2009 Dec; 24(12):3708-12. PubMed ID: 19602475
[TBL] [Abstract][Full Text] [Related]
10. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
Lee HT; Shiao YM; Wu TH; Chen WS; Hsu YH; Tsai SF; Tsai CY
J Rheumatol; 2010 Jan; 37(1):45-52. PubMed ID: 19955043
[TBL] [Abstract][Full Text] [Related]
11. B-cell-attracting chemokine-1 (BCA-1/CXCL13) in systemic lupus erythematosus, its correlation to disease activity and renal involvement.
Hafez SS; Saad Wel S; Shedid NH
Egypt J Immunol; 2014; 21(2):23-32. PubMed ID: 25812350
[TBL] [Abstract][Full Text] [Related]
12. Assessment of anti-nucleosome antibody (ANuA) isotypes for the diagnosis and prediction of systemic lupus erythematosus and lupus nephritis activity.
Zeng Y; Xiao Y; Zeng F; Jiang L; Yan S; Wang X; Lin Q; Yu L; Lu X; Zhang Y; Lin Y
Clin Exp Med; 2023 Sep; 23(5):1677-1689. PubMed ID: 36385418
[TBL] [Abstract][Full Text] [Related]
13. Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud's arthropathy.
Ribeiro DS; Lins CF; Galvão V; Santos WGD; Rosa G; Machicado V; Pedreira AL; da Fonseca EP; Souza APMD; Baleeiro C; Ferreira LG; Oliveira IS; Gama da Silva JPC; Atta AM; Santiago MB
Lupus; 2018 May; 27(6):939-946. PubMed ID: 29338586
[TBL] [Abstract][Full Text] [Related]
14. The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: A STROBE-compliant article.
Fang C; Luo T; Lin L
Medicine (Baltimore); 2017 Dec; 96(48):e8675. PubMed ID: 29310341
[TBL] [Abstract][Full Text] [Related]
15. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.
Mok CC; Soliman S; Ho LY; Mohamed FA; Mohamed FI; Mohan C
Arthritis Res Ther; 2018 Jan; 20(1):6. PubMed ID: 29325582
[TBL] [Abstract][Full Text] [Related]
16. Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity.
Shang X; Ren L; Sun G; Yu T; Yao Y; Wang L; Liu F; Zhang L; He X; Liu M
Immun Inflamm Dis; 2021 Jun; 9(2):407-418. PubMed ID: 33470559
[TBL] [Abstract][Full Text] [Related]
17. Validity of immunoglobulin-binding protein 1 as a biomarker for lupus nephritis.
Ebaid AM; Ezzeldin N; Abdelhady EI; Mohammed HA; Abdallah AL
Lupus; 2023 Jan; 32(1):101-110. PubMed ID: 36418233
[TBL] [Abstract][Full Text] [Related]
18. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
[TBL] [Abstract][Full Text] [Related]
19. CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice.
Wu X; Guo J; Ding R; Lv B; Bi L
Acta Histochem; 2015 Oct; 117(8):732-7. PubMed ID: 26456520
[TBL] [Abstract][Full Text] [Related]
20. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity.
Wong CK; Wong PT; Tam LS; Li EK; Chen DP; Lam CW
J Clin Immunol; 2010 Jan; 30(1):45-52. PubMed ID: 19774453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
